CO5011113A1 - Derivados de acido 3-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz y composiciones farmaceuticas que los contienen - Google Patents

Derivados de acido 3-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz y composiciones farmaceuticas que los contienen

Info

Publication number
CO5011113A1
CO5011113A1 CO97025167A CO97025167A CO5011113A1 CO 5011113 A1 CO5011113 A1 CO 5011113A1 CO 97025167 A CO97025167 A CO 97025167A CO 97025167 A CO97025167 A CO 97025167A CO 5011113 A1 CO5011113 A1 CO 5011113A1
Authority
CO
Colombia
Prior art keywords
molecular weight
low molecular
alkyl
weight alkyl
phenyl
Prior art date
Application number
CO97025167A
Other languages
English (en)
Inventor
Kluender Harold C E
Brian R Dixon
David R Britelli
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CO5011113A1 publication Critical patent/CO5011113A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos con actividad inhibitoria de la metaloproteinasade matriz que tienen la fórmula generalizada: en la cual R1 representa un sustituyente independientemente seleccionado entre el grupo que consiste en alquilo C6 -C12 ; alcoxi C5 -C12 ; alquiltio C5 -C12 ; poliéter de la fórmula R2 O(C2 H4 O)a -; donde a es 1 ó 2; y R2 es alquilo C1 -C5 ; fenilo o bencilo; y alquinilo sustituido de la fórmula R3 (CH2 )b -C=C- en la cual el b es 1-10 y R3 es H-, HO- o R4 O- donde R4 es alquilo C1 -C3 ; fenilo, o bencilo; Las porciones alquilo, fenilo y bencilo de R1 pueden contener por lo menos un sustituyente farmacéuticamente aceptable seleccionado entre halógeno, alquilo de bajo peso molecular, haloalquilo, -VN, -NO2 , -CO2 R6 , -OCOR6 , CH2 OR6 , -CONR6 R7 , -COR6 Y -OR8 en donde R6 representa H o alquilo de bajo peso molecular; H o alquilo de bajo peso molecular; R6 y R7 juntos con el nitrógeno al cual están unidos forman un anillo morfolina; y R8 representa H, alquilo de bajo peso molecular o haloalquilo; el subíndice n es 2-4; R5 representa un sustituyente independientemente seleccionado entre el grupo que consiste en fenilo; imidoilo de 4-12 átomos de carbono; (3H)-benzo-1,2,3-triazin-4-on-3-ilo; N-sacarinilo; (2H)-ftalazin-1-on-2-ilo; 2-benzoxazolin-2-on-3-ilo; 5,5-dimetiloxazolidin-2,4-dion-3-ilo; y tiazolidin-2,4-dion-3-ilo; las porciones fenilo y benzo de R5 pueden contener por lo menos un sustituyente farmacéuticamente aceptable seleccionado entre halógeno, alquilo de bajo peso molecular, haloalquilo, -CN, -NO2 , -CO2 R6 , -OCOR6 , CH2 OR6 , -CONR6 R7 , COR6 , Y -OR8 , en donde R6 representa H o alquilo de bajo peso molecular; R7 representa H o alquilo de bajo peso molecular; o R6 y R7 juntos con el nitrógeno al cual están unidos forman un anillo morfolina; y R8 representa H, alquilo de bajo peso molecular o haloalquilo; y las sales farmacéuticamente aceptables de los mismos.
CO97025167A 1996-05-15 1997-05-09 Derivados de acido 3-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz y composiciones farmaceuticas que los contienen CO5011113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64768296A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
CO5011113A1 true CO5011113A1 (es) 2001-02-28

Family

ID=24597888

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97025167A CO5011113A1 (es) 1996-05-15 1997-05-09 Derivados de acido 3-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz y composiciones farmaceuticas que los contienen

Country Status (21)

Country Link
EP (1) EP0923529B1 (es)
JP (1) JP3354941B2 (es)
CN (1) CN1225620A (es)
AR (1) AR007101A1 (es)
AT (1) ATE205822T1 (es)
AU (1) AU727468B2 (es)
BR (1) BR9709075A (es)
CA (1) CA2253795C (es)
CO (1) CO5011113A1 (es)
DE (1) DE69706874T2 (es)
ES (1) ES2160955T3 (es)
HR (1) HRP970247B1 (es)
ID (1) ID17326A (es)
MY (1) MY116903A (es)
PA (1) PA8429501A1 (es)
SV (1) SV1997000033A (es)
TN (1) TNSN97086A1 (es)
TW (1) TW442468B (es)
WO (1) WO1997043237A1 (es)
YU (1) YU18897A (es)
ZA (1) ZA974033B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
FR2832925B1 (fr) * 2001-12-03 2006-07-14 Lipha Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
JP2012087113A (ja) * 2010-09-22 2012-05-10 Daicel Corp フェニル酢酸化合物
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
CN106661008A (zh) * 2014-04-03 2017-05-10 拜耳制药股份公司 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
WO2015150364A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituierte benzotriazinonbutansäuren und ihre verwendung
US20170121315A1 (en) * 2014-06-12 2017-05-04 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE650081A (es) * 1963-07-03
FR2378741A1 (fr) * 1977-02-01 1978-08-25 Fabre Sa Pierre Acides garyl goxo isovaleriques doues de proprietes antiphlogistiques et antalgiques

Also Published As

Publication number Publication date
SV1997000033A (es) 1999-01-14
ATE205822T1 (de) 2001-10-15
CA2253795C (en) 2002-10-15
DE69706874D1 (en) 2001-10-25
JP3354941B2 (ja) 2002-12-09
EP0923529A1 (en) 1999-06-23
YU18897A (en) 1999-11-22
MY116903A (en) 2004-04-30
WO1997043237A1 (en) 1997-11-20
AU727468B2 (en) 2000-12-14
ZA974033B (en) 1998-02-19
HRP970247A2 (en) 1998-04-30
DE69706874T2 (de) 2002-03-28
ES2160955T3 (es) 2001-11-16
TW442468B (en) 2001-06-23
PA8429501A1 (es) 2000-05-24
CN1225620A (zh) 1999-08-11
CA2253795A1 (en) 1997-11-20
AR007101A1 (es) 1999-10-13
BR9709075A (pt) 1999-08-03
HRP970247B1 (en) 2002-02-28
TNSN97086A1 (fr) 2005-03-15
AU2938997A (en) 1997-12-05
EP0923529B1 (en) 2001-09-19
ID17326A (id) 1997-12-18
JPH11510518A (ja) 1999-09-14

Similar Documents

Publication Publication Date Title
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
CO5251440A1 (es) Derivados de heterociclil-fenil-oxazolidin-tiofencarboxamida, su procedimiento de obtencion y medicamentos que los contienen
DOP2006000063A (es) Derivados de ciclopropanocarboxamida
ECSP066966A (es) Compuestos de aril-o heteroarilamida ortosustituidos
CO5640090A2 (es) Inhibidores del factor inhibidor de la migracion de los macrofagos y etodo para su identificacion
DE68913930D1 (de) Serotonin- und Norepinephrin-Aufnahme-Inhibitoren.
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
OA07075A (fr) Nouveaux benzo [b] thiophène, benzo [b] furannes, thiochromannes et chromannés ayant une activité antimicrobienne.
DK1152009T3 (da) Hidtil ukendte nucleosider og oligonucleotid-analoger
ES2066828T3 (es) Nucleosidos y nucleotidos carbociclicos.
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
ES2196772T3 (es) Compuestos amino ciclicos.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR004662A1 (es) Nuevos derivados de arilglicinamida, procedimiento para su preparacion, composiciones farmaceuticas que contienen estos compuestos y su utilizacionpara preparar medicamentos y combatir y prevenir enfermedades.
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
CO5011113A1 (es) Derivados de acido 3-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz y composiciones farmaceuticas que los contienen
CO5011045A1 (es) Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos
HUP0203188A2 (hu) Eljárás 5-ös helyzetben nitrált benzofurán- és benzotiofénszármazékok előállítására és ezek alkalmazása
AR039927A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen
MX9202438A (es) Esteroides 3-carboxi insaturados substituidos en la posicion 17 beta, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ATE102611T1 (de) Thiazol-derivate.
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
ES2172294T3 (es) Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DK0514942T3 (da) Hidtil ukendte benzopyranderivater og fremgangsmåder til fremstilling deraf